Frontline gastroenterology · 2024
Optimising triage of urgent referrals for suspected IBD: results from the Birmingham IBD inception study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rimmer Peter, Cheesbrough Jonathan, Harris Jane, Love Melanie, Tull Samantha, Iqbal Asif, Regan-Komito Daniel, Cooney Rachel, Hazel Karl, Sharma Naveen, Dietrich Thomas, Chapple Iain, Quraishi Mohammad Nabil, Iqbal Tariq H
Аннотация
OBJECTIVE: Diagnostic delays in inflammatory bowel disease (IBD) result in adverse outcomes. We report a bespoke diagnostic pathway to assess how best to combine clinical history and faecal calprotectin (FCP) for early diagnosis and efficient resource utilisation.
METHODS: A rapid-access pathway was implemented for suspected IBD patients referred outside urgent 'two-week wait' criteria. Patients were triaged using symptoms and FCP. A 13-point symptom history was taken prediagnosis and clinical indices, including repeat FCP, collected prospectively.
RESULTS: Of 767 patients (January 2021-August 2023), 423 were diagnosed with IBD (208 Crohn's disease (CD), 215 ulcerative colitis (UC)). Most common symptoms in CD were abdominal pain (84%), looser stools (84%) and fatigue (79%) and in UC per-rectal bleeding (94%), urgency (82%) and looser stools (81%). Strongest IBD predictors were blood mixed with stools (CD OR 4.38; 95% CI 2.40-7.98, UC OR 33.68; 15.47-73.33) and weight loss (CD OR 3.39; 2.14-5.38, UC OR 2.33; 1.37-4.00). Repeat FCP testing showed reduction from baseline in non-IBD. Both measurements >100 µg/g (area under the curve (AUC) 0.800) and >200 µg/g (AUC 0.834) collectively predicted IBD. However, a second value ≥220 µg/g considered alone, regardless of the first result, was more accurate (Youden's index 0.735, AUC 0.923). Modelling symptoms with FCP increased AUC to 0.947.
CONCLUSION: Serial FCP measurement prevents unnecessary colonoscopy. Two FCPs >200 µg/g could stream patients direct to colonoscopy, with two >100 µg/g prompting clinic review. A second result ≥220 µg/g was more accurate than dual-result thresholds. Coupling home FCP testing with key symptoms may form the basis of effective self-referral pathways.
METHODS: A rapid-access pathway was implemented for suspected IBD patients referred outside urgent 'two-week wait' criteria. Patients were triaged using symptoms and FCP. A 13-point symptom history was taken prediagnosis and clinical indices, including repeat FCP, collected prospectively.
RESULTS: Of 767 patients (January 2021-August 2023), 423 were diagnosed with IBD (208 Crohn's disease (CD), 215 ulcerative colitis (UC)). Most common symptoms in CD were abdominal pain (84%), looser stools (84%) and fatigue (79%) and in UC per-rectal bleeding (94%), urgency (82%) and looser stools (81%). Strongest IBD predictors were blood mixed with stools (CD OR 4.38; 95% CI 2.40-7.98, UC OR 33.68; 15.47-73.33) and weight loss (CD OR 3.39; 2.14-5.38, UC OR 2.33; 1.37-4.00). Repeat FCP testing showed reduction from baseline in non-IBD. Both measurements >100 µg/g (area under the curve (AUC) 0.800) and >200 µg/g (AUC 0.834) collectively predicted IBD. However, a second value ≥220 µg/g considered alone, regardless of the first result, was more accurate (Youden's index 0.735, AUC 0.923). Modelling symptoms with FCP increased AUC to 0.947.
CONCLUSION: Serial FCP measurement prevents unnecessary colonoscopy. Two FCPs >200 µg/g could stream patients direct to colonoscopy, with two >100 µg/g prompting clinic review. A second result ≥220 µg/g was more accurate than dual-result thresholds. Coupling home FCP testing with key symptoms may form the basis of effective self-referral pathways.